Intellicell Biosciences Inc (SVFC) financial statements (2021 and earlier)

Company profile

Business Address 30 EAST 76TH STREET, 6TH FLOOR
NEW YORK, NY 10021
State of Incorp. NV
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 10
Cash and cash equivalents 10
Receivables 285
Other current assets9
Total current assets:9296
Noncurrent Assets
Property, plant and equipment2,6702,797
Restricted cash and investments 650
Other undisclosed noncurrent assets534193
Total noncurrent assets:3,2053,640
TOTAL ASSETS:3,2143,935
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2,6092,162
Accounts payable2,0211,377
Accrued liabilities 42
Employee-related liabilities434274
Other undisclosed accounts payable and accrued liabilities154470
Debt8411,609
Due to related parties 1,115
Other undisclosed current liabilities5,8382,198
Total current liabilities:9,2887,083
Noncurrent Liabilities
Other undisclosed noncurrent liabilities3,775987
Total noncurrent liabilities:3,775987
Total liabilities:13,0638,070
Stockholders' equity
Stockholders' equity attributable to parent, including:(9,849)(4,135)
Common stock9259
Additional paid in capital38,96133,568
Accumulated deficit(48,903)(37,763)
Other undisclosed stockholders' equity attributable to parent11
Total stockholders' equity:(9,849)(4,135)
TOTAL LIABILITIES AND EQUITY:3,2143,935

Income statement (P&L) ($ in thousands)

12/31/2013
12/31/2012
Revenues
(Revenue, Net)
 535
Cost of revenue
(Cost of Goods and Services Sold)
(300)(466)
Gross profit:(300)69
Operating expenses(5,521)(14,940)
Other undisclosed operating income300 
Operating loss:(5,521)(14,872)
Nonoperating expense(5,620)(10,720)
Investment income, nonoperating2,788(13,804)
Interest and debt expense(2,527)213
Loss from continuing operations before equity method investments, income taxes:(13,668)(25,378)
Other undisclosed income from continuing operations before income taxes2,52721,226
Net loss available to common stockholders, diluted:(11,141)(4,152)

Comprehensive Income ($ in thousands)

12/31/2013
12/31/2012
Net loss:(11,141)(4,152)
Comprehensive loss, net of tax, attributable to parent:(11,141)(4,152)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: